CalciMedica Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CALC$1.37-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(a)
Documents filed as a part of the report:
(1)
Financial Statements. The following financial statements of CalciMedica, Inc., together with the report of Ernst & Young LLP, an independent registered public accounting firm, required to be filed pursuant to Part II, Item 8 of this Annual Report are included on the following pages:
| Report of Independent Registered Public Accounting Firm PCAOB ID: 42 | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years ended December 31, 2023 and 2022 | F-6 |
| Consolidated Statements of Cash Flows for the Years ended December 31, 2023 and 2022 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
(2)Financial Statement Schedules. None
(3) List of exhibits required by Item 601 of Regulation S-K. See part (b) below.
(b) Exhibits
Exhibit Index
| ExhibitNumber | Description | Form | File No. | ExhibitFiling Date | ExhibitNo. | Filed/FurnishedHerewith |
|---|---|---|---|---|---|---|
| 2.1‡ | Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, by and among Graybug Vision, Inc.,Camaro Merger Sub, Inc. and CalciMedica, Inc., as amended by the First Amendment, dated February 10, 2023. | 8-K | 001-39538 | March 22, 2023 | 2.1 | |
| 3.1 | Amended and Restated Certificate of Incorporation of the registrant. | 8-K | 001-39538 | March 22, 2023 | 3.1 | |
| 3.2 | Certificate of Amendment, dated March 20, 2023 to Amended and Restated Certificate of Incorporation of the registrant. | 8-K | 001-39538 | March 22, 2023 | 3.2 | |
| 3.3 | Restated Bylaws of the registrant. | 10-Q | 001-39538 | November 12, 2020 | 3.2 | |
| 4.1 | Reference is made to Exhibits 3.1, 3.2 and 3.3. | |||||
| 4.2 | Description of Registrant’s Common Stock | X | ||||
| 4.3 | Form of Common Stock Certificate | S-1/A | 333-248611 | September 21, 2020 | 4.1 | |
| ExhibitNumber · Description · Form · File No. · ExhibitFiling Date · ExhibitNo. · Filed/FurnishedHerewith | |||||
|---|---|---|---|---|---|
| 4.4 | Form of Registration Rights Agreement, dated November 21, 2022, by and among CalciMedica, Inc. and the several purchasers signatory thereto. | 8-K | 001-39538 | March 22, 2023 | 4.1 |
| 4.5 | Form of Registration Rights Agreement by and among CalciMedica, Inc. and the persons party thereto. | 8-K | 001-39538 | January 24, 2024 | 10.2 |
| 4.6 | Warrant to Purchase Common Stock, dated December 11, 2019, by and between the Registrant and SG DAN Equity Holdings, LLC. | S-1 | 333-248611 | September 4, 2020 | 4.3 |
| 4.7 | Form of Warrant to Purchase Shares of Series D Convertible Preferred Stock of CalciMedica, Inc. | 8-K | 001-39538 | March 22, 2023 | 4.2 |
| 4.8 | Warrant to Purchase Common Stock dated as of November 9, 2020, issued by CalciMedica, Inc. to SG Dan Equity Holdings, LLC. | 8-K | 001-39538 | March 22, 2023 | 4.3 |
| 4.9 | Warrant to Purchase Common Stock, dated as of October 18, 2022, issued by CalciMedica, Inc. to SG Dan Equity Holdings, LLC. | 8-K | 001-39538 | March 22, 2023 | 4.4 |
| 4.10 | Warrant to Purchase Common Stock, dated as of October 18, 2022, issued by CalciMedica, Inc. to Eric Roberts. | 8-K | 001-39538 | March 22, 2023 | 4.5 |
| 4.11 | Warrant to Purchase Common Stock, dated as of October 25,2022, issued by CalciMedica, Inc. to Fred Middleton. | 8-K | 001-39538 | March 22, 2023 | 4.6 |
| 4.12 | Form of Warrant to Purchase Shares of Series B Convertible Preferred Stock of CalciMedica, Inc. | S-3 | 333-271115 | April 4, 2023 | 4.9 |
| 4.13 | Form of Tranche A Common Warrant. | 8-K | 001-39538 | January 24, 2024 | 4.1 |
| 4.14 | Form of Tranche B Common Warrant. | 8-K | 001-39538 | January 24, 2024 | 4.2 |
| 4.15 | Form of Pre-Funded Warrant. | 8-K | 001-39538 | January 24, 2024 | 4.3 |
| 4.16 | Form of Placement Agent Warrant. | 8-K | 001-39538 | January 24, 2024 | 4.4 |
| 10.1+ | Offer Letter between CalciMedica, Inc. and A. Rachel Leheny, Ph.D., dated May 20, 2020. | 8-K | 001-39538 | March 22, 2023 | 10.1 |
| ExhibitNumber · Description · Form · File No. · ExhibitFiling Date · ExhibitNo. · Filed/FurnishedHerewith | |||||
|---|---|---|---|---|---|
| 10.2+ | Offer Letter between CalciMedica, Inc. and Eric Roberts, dated May 20, 2020. | 8-K | 001-39538 | March 22, 2023 | 10.2 |
| 10.3+ | Offer Letter between CalciMedica, Inc. and Sudarshan Hebbar, M.D., dated August 24, 2015. | 8-K | 001-39538 | March 22, 2023 | 10.3 |
| 10.4+ | Offer Letter between CalciMedica, Inc. and Michael Dunn, dated August 29, 2014. | 8-K | 001-39538 | March 22, 2023 | 10.4 |
| 10.5+ | Offer Letter between CalciMedica, Inc. and Kenneth A. Stauderman, Ph.D., dated August 29, 2014. | 8-K | 001-39538 | March 22, 2023 | 10.5 |
| 10.6+ | Consulting Agreement, dated as of October 26, 2020, by and between the CalciMedica, Inc. and Danforth Advisors, LLC. | 8-K | 001-39538 | March 22, 2023 | 10.11 |
| 10.7+ | CalciMedica, Inc. 2023 Equity Incentive Plan. | 8-K | 001-39538 | March 22, 2023 | 10.6 |
| 10.8+ | Forms of Option Grant Notice and Option Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan. | 8-K | 001-39538 | March 22, 2023 | 10.7 |
| 10.9+ | Forms of Restricted Stock Unit Grant Notice and Unit Award Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan. | 8-K | 001-39538 | March 22, 2023 | 10.8 |
| 10.10+ | CalciMedica, Inc. 2023 Employee Stock Purchase Plan. | 8-K | 001-39538 | March 22, 2023 | 10.9 |
| 10.11+ | CalciMedica, Inc. 2006 Stock Plan and Form of Stock Option Agreement thereunder. | 8-K | 001-39538 | March 22, 2023 | 10.10 |
| 10.12+ | 2020 Equity Incentive Plan and forms of award agreements. | S-1/A | 333-248611 | September 21, 2020 | 10.3 |
| 10.13+ | 2020 Employee Stock Purchase Plan and forms of award agreements. | S-1/A | 333-248611 | September 21, 2020 | 10.4 |
| 10.14+ | Form of Amendment to Stock Option Award Agreement, dated March 20, 2023, by and between Graybug Vision, Inc. and the Holder party thereto | 8-K | 001-39538 | March 22, 2023 | 10.12 |
| 10.15+ | Form of Amendment to Restricted Stock Unit Award Agreement, dated March 20, 2023, by and between Graybug Vision, Inc. and the Holder party thereto | 8-K | 001-39538 | March 22, 2023 | 10.13 |
| 10.16+ | 2015 Stock Incentive Plan, as amended, and forms of award agreements thereunder. | S-1 | 333-248611 | September 4, 2020 | 10.2 |
| ExhibitNumber | Description | Form | File No. | ExhibitFiling Date | ExhibitNo. | Filed/FurnishedHerewith |
|---|---|---|---|---|---|---|
| 10.17+ | Form of Indemnification Agreement. | S-1 | 333-248611 | September 4, 2020 | 10.1 | |
| 10.18+ | Change in Control and Severance Policy. | S-1 | 333-248611 | September 4, 2020 | 10.11 | |
| 10.19 | At the Market Offering Agreement, dated as of August 11, 2023, by and between CalciMedica, Inc. and H.C. Wainwright & Co., LLC | S-3 | 333-273949 | August 11, 2023 | 1.2 | |
| X | ||||||
| 21.1 | List of Subsidiaries | |||||
| 23.1 | Consent of Independent Registered Public Accounting Firm | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 97.1 | CalciMedica, Inc. Incentive Compensation Recoupment Policy | X | ||||
| 101.INS | Inline XBRL Instance Document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. | X | ||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | X | ||||
- This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act.
- Indicates management contract or compensatory plan.
‡ Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.